BRST5:Volunteer Assignments and Opportunities - Revision history

Jennelleh at 14:39, 1 October 2025

2025-10-01T14:39:33Z

← Older revision		Revision as of 09:39, 1 October 2025
Line 764:		Line 764:
	----		----
	\|-		\|-
	\|[[BRST5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]\|\|Disease\|\|		\|[[BRST5:Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]\|\|Disease\|\|[[HAEM5:Volunteer Assignments and Opportunities\|See HAEM5 volunteer sheet for authorship status]]
	\|		\|
	\|		\|
Line 773:		Line 773:
	\|		\|
	\|-		\|-
	\|[[BRST5:Follicular lymphoma\|Follicular lymphoma]]\|\|Disease\|\|		\|[[BRST5:Follicular lymphoma\|Follicular lymphoma]]\|\|Disease\|\|[[HAEM5:Volunteer Assignments and Opportunities\|See HAEM5 volunteer sheet for authorship status]]
	\|		\|
	\|		\|
Line 793:		Line 793:
	!'''Notes'''		!'''Notes'''
	\|-		\|-
	\|[[BRST5:Diffuse large B-cell lymphoma\|Diffuse large B-cell lymphoma]]\|\|Disease\|\|		\|[[BRST5:Diffuse large B-cell lymphoma\|Diffuse large B-cell lymphoma]]\|\|Disease\|\|[[HAEM5:Volunteer Assignments and Opportunities\|See HAEM5 volunteer sheet for authorship status]]
	\|		\|
	\|		\|
Line 802:		Line 802:
	\|		\|
	\|-		\|-
	\|[[BRST5:Burkitt lymphoma\|Burkitt lymphoma]]\|\|Disease\|\|		\|[[BRST5:Burkitt lymphoma\|Burkitt lymphoma]]\|\|Disease\|\|[[HAEM5:Volunteer Assignments and Opportunities\|See HAEM5 volunteer sheet for authorship status]]
	\|		\|
	\|		\|

Richard.Glen: Formatted Author Names

2025-09-24T21:37:56Z

Formatted Author Names

← Older revision		Revision as of 16:37, 24 September 2025
Line 363:		Line 363:
	\|		\|
	\|-		\|-
	\|[[BRST5:Adenoid cystic carcinoma\|Adenoid cystic carcinoma]]\|\|Disease\|\|Katherine Geiersbach / Jun Liao		\|[[BRST5:Adenoid cystic carcinoma\|Adenoid cystic carcinoma]]\|\|Disease\|\|Katherine Geiersbach;
			Jun Liao
	\|10/12/02022		\|10/12/02022
	\|11/11/2023		\|11/11/2023
Line 372:		Line 373:
	\|2024 template added		\|2024 template added
	\|-		\|-
	\|[[BRST5:Secretory carcinoma\|Secretory carcinoma]]\|\|Disease\|\|Hui Chen / Katherine Geiersbach		\|[[BRST5:Secretory carcinoma\|Secretory carcinoma]]\|\|Disease\|\|Hui Chen;
			Katherine Geiersbach
	\|10/12/2022		\|10/12/2022
	\|11/11/2023		\|11/11/2023
Line 476:		Line 478:
	\|		\|
	\|-		\|-
	\|[[BRST5:Phyllodes tumour\|Phyllodes tumour]]\|\|Disease\|\|Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach		\|[[BRST5:Phyllodes tumour\|Phyllodes tumour]]\|\|Disease\|\|Emilie Lalonde;
			H. Evin Gulbahce;

			Katherine Geiersbach
	\|8/11/2023		\|8/11/2023
	\|11/11/2023		\|11/11/2023

Jennelleh at 15:57, 23 September 2025

2025-09-23T15:57:20Z

← Older revision		Revision as of 10:57, 23 September 2025
Line 262:		Line 262:
	\|		\|
	\|-		\|-
	\|[[BRST5:Microinvasive carcinoma\|Microinvasive carcinoma]]\|\|Disease\|\|		\|[[BRST5:Microinvasive carcinoma\|Microinvasive carcinoma]]\|\|Disease\|\|Hieu Nguyen
	\|		\|9/23/2025
	\|
	\|
	\|		\|
			\|PENDING
	\|		\|
			\|Katherine Geiersbach
	\|		\|
	\|		\|

Kgeiersbach at 12:10, 5 September 2025

2025-09-05T12:10:26Z

← Older revision		Revision as of 07:10, 5 September 2025
Line 69:		Line 69:
	\|		\|
	\|-		\|-
	\| [[BRST5:Sclerosing adenosis\|Sclerosing adenosis]]\|\|Disease\|\|		\|[[BRST5:Sclerosing adenosis\|Sclerosing adenosis]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 354:		Line 354:
	\|		\|
	\|-		\|-
	\|[[BRST5:Acinic cell carcinoma\|Acinic cell carcinoma]]\|\|Disease\|\|~~Patricija Zot~~		\|[[BRST5:Acinic cell carcinoma\|Acinic cell carcinoma]]\|\|Disease\|\|
	\|~~2/28/2024~~		\|
			\|
			\|
	\|		\|
	~~\|PENDING~~
	\|		\|
	~~\|Katherine Geiersbach~~
	\|		\|
	\|		\|
Line 467:		Line 467:
	\|		\|
	\|-		\|-
	\|[[BRST5:Fibroadenoma\|Fibroadenoma]]\|\|~~Disease~~\|\|~~H. Evin Gulbahce / Patricija Zot~~		\|[[BRST5:Fibroadenoma\|Fibroadenoma]]\|\| \|\|
			\|
			\|
	\|		\|
	\|		\|
	~~\|PENDING~~
	\|		\|
	\|		\|
	\|		\|
	~~\|2024 template added~~
	\|-		\|-
	\|[[BRST5:Phyllodes tumour\|Phyllodes tumour]]\|\|Disease\|\|Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach		\|[[BRST5:Phyllodes tumour\|Phyllodes tumour]]\|\|Disease\|\|Emilie Lalonde / H. Evin Gulbahce /Katherine Geiersbach

Bailey.Glen at 16:54, 24 April 2025

2025-04-24T16:54:12Z

← Older revision		Revision as of 11:54, 24 April 2025
Line 854:		Line 854:
	\|		\|
	\|-		\|-
	\|[[BRST5:Invasive carcinoma\|Invasive carcinoma]\|\|Disease\|\|		\|[[BRST5:Invasive carcinoma\|Invasive carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 863:		Line 863:
	\|		\|
	\|-		\|-
	\|[[BRST5:Metastases to the breast\|Metastases to the breast]\|\|Disease\|\|		\|[[BRST5:Metastases to the breast\|Metastases to the breast]]\|\|Disease\|\|
	\|		\|
	\|		\|

Bailey.Glen at 16:50, 24 April 2025

2025-04-24T16:50:43Z

Show changes

Bailey.Glen at 16:36, 24 April 2025

2025-04-24T16:36:05Z

← Older revision		Revision as of 11:36, 24 April 2025
Line 60:		Line 60:
	\|		\|
	\|-		\|-
	\|[[BRST5:Atypical ductal hyperplasia\|Atypical ductal hyperplasia]\|\|Disease\|\|		\|[[BRST5:Atypical ductal hyperplasia\|Atypical ductal hyperplasia]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 188:		Line 188:
	\|		\|
	\|-		\|-
	\|Encapsulated papillary carcinoma\|\|Disease\|\|		\|[[BRST5:Encapsulated papillary carcinoma\|Encapsulated papillary carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 197:		Line 197:
	\|		\|
	\|-		\|-
	\|Solid papillary carcinoma (in situ and invasive)\|\|Disease\|\|		\|[[BRST5:Solid papillary carcinoma (in situ and invasive)\|Solid papillary carcinoma (in situ and invasive)[[\|\|Disease\|\|
	\|		\|
	\|		\|
Line 206:		Line 206:
	\|		\|
	\|-		\|-
	\|Invasive papillary carcinoma\|\|Disease\|\|		\|[[BRST5:Invasive papillary carcinoma\|Invasive papillary carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 215:		Line 215:
	\|		\|
	\|-		\|-
	\|Atypical lobular hyperplasia\|\|Disease\|\|		\|[[BRST5:Atypical lobular hyperplasia\|Atypical lobular hyperplasia]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 235:		Line 235:
	!'''Notes'''		!'''Notes'''
	\|-		\|-
	\|Lobular carcinoma in situ\|\|Disease\|\|		\|[[BRST5:Lobular carcinoma in situ\|Lobular carcinoma in situ]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 244:		Line 244:
	\|		\|
	\|-		\|-
	\|Ductal carcinoma in situ\|\|Disease\|\|		\|[[BRST5:Ductal carcinoma in situ\|Ductal carcinoma in situ]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 253:		Line 253:
	\|		\|
	\|-		\|-
	\|Invasive breast carcinoma of no special type\|\|Disease\|\|		\|[[BRST5:Invasive breast carcinoma of no special type\|Invasive breast carcinoma of no special type]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 262:		Line 262:
	\|		\|
	\|-		\|-
	\|Microinvasive carcinoma\|\|Disease\|\|		\|[[BRST5:Microinvasive carcinoma\|Microinvasive carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 271:		Line 271:
	\|		\|
	\|-		\|-
	\|Invasive lobular carcinoma\|\|Disease\|\|		\|[[BRST5:Invasive lobular carcinoma\|Invasive lobular carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 280:		Line 280:
	\|		\|
	\|-		\|-
	\|Tubular carcinoma\|\|Disease\|\|		\|[[BRST5:Tubular carcinoma\|Tubular carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 289:		Line 289:
	\|		\|
	\|-		\|-
	\|Cribriform carcinoma\|\|Disease\|\|		\|[[BRST5:Cribriform carcinoma\|Cribriform carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 298:		Line 298:
	\|		\|
	\|-		\|-
	\|Mucinous carcinoma\|\|Disease\|\|		\|[[BRST5:Mucinous carcinoma\|Mucinous carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 307:		Line 307:
	\|		\|
	\|-		\|-
	\|Mucinous cystadenocarcinoma\|\|Disease\|\|		\|[[BRST5:Mucinous cystadenocarcinoma\|Mucinous cystadenocarcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 316:		Line 316:
	\|		\|
	\|-		\|-
	\|Invasive micropapillary carcinoma\|\|Disease\|\|		\|[[BRST5:Invasive micropapillary carcinoma\|Invasive micropapillary carcinoma]]\|\|Disease\|\|
	\|		\|
	\|		\|

Bailey.Glen at 16:31, 24 April 2025

2025-04-24T16:31:31Z

← Older revision		Revision as of 11:31, 24 April 2025
Line 60:		Line 60:
	\|		\|
	\|-		\|-
	\|Atypical ductal hyperplasia\|\|Disease\|\|		\|[[BRST5:Atypical ductal hyperplasia\|Atypical ductal hyperplasia]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 69:		Line 69:
	\|		\|
	\|-		\|-
	\|Sclerosing adenosis\|\|Disease\|\|		\| [[BRST5:Sclerosing adenosis\|Sclerosing adenosis]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 78:		Line 78:
	\|		\|
	\|-		\|-
	\|Apocrine adenosis and adenoma\|\|Disease\|\|		\|[[BRST5:Apocrine adenosis and adenoma\|Apocrine adenosis and adenoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 87:		Line 87:
	\|		\|
	\|-		\|-
	\|Microglandular adenosis\|\|Disease\|\|		\|[[BRST5:Microglandular adenosis\|Microglandular adenosis]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 96:		Line 96:
	\|		\|
	\|-		\|-
	\|Radial scar/complex sclerosing lesion\|\|Disease\|\|		\|[[BRST5:Radial scar / complex sclerosing lesion\|Radial scar/complex sclerosing lesion]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 105:		Line 105:
	\|		\|
	\|-		\|-
	\|Tubular adenoma\|\|Disease\|\|		\|[[BRST5:Tubular adenoma\|Tubular adenoma]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 114:		Line 114:
	\|		\|
	\|-		\|-
	\|Lactating adenoma\|\|Disease\|\|		\|[[BRST5:Lactating adenoma\|Lactating adenoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 134:		Line 134:
	!'''Notes'''		!'''Notes'''
	\|-		\|-
	\|Ductal adenoma\|\|Disease\|\|		\|[[BRST5:Ductal adenoma\|Ductal adenoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 143:		Line 143:
	\|		\|
	\|-		\|-
	\|Pleomorphic adenoma\|\|Disease\|\|		\|[[BRST5:Pleomorphic adenoma\|Pleomorphic adenoma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 152:		Line 152:
	\|		\|
	\|-		\|-
	\|Adenomyoepithelioma\|\|Disease\|\|		\|[[BRST5:Adenomyoepithelioma\|Adenomyoepithelioma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 161:		Line 161:
	\|		\|
	\|-		\|-
	\|Malignant adenomyoepithelioma\|\|Disease\|\|		\|[[BRST5:Malignant adenomyoepithelioma\|Malignant adenomyoepithelioma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 170:		Line 170:
	\|		\|
	\|-		\|-
	\|Intraductal papilloma\|\|Disease\|\|		\|[[BRST5:Intraductal papilloma\|Intraductal papilloma]]\|\|Disease\|\|
	\|		\|
	\|		\|
Line 179:		Line 179:
	\|		\|
	\|-		\|-
	\|Papillary ductal carcinoma in situ\|\|Disease\|\|		\|[[BRST5:Papillary ductal carcinoma in situ\|Papillary ductal carcinoma in situ]]\|\|Disease\|\|
	\|		\|
	\|		\|

Bailey.Glen at 16:27, 24 April 2025

2025-04-24T16:27:21Z

← Older revision		Revision as of 11:27, 24 April 2025
Line 51:		Line 51:
	\|		\|
	\|-		\|-
	\|Columnar cell lesions, including flat epithelial atypia\|\|Disease\|\|		\|[[BRST5:Columnar cell lesions, including flat epithelial atypia\|Columnar cell lesions, including flat epithelial atypia]]\|\|Disease\|\|
	\|		\|
	\|		\|

Bailey.Glen at 16:26, 24 April 2025

2025-04-24T16:26:19Z

← Older revision		Revision as of 11:26, 24 April 2025
Line 40:		Line 40:
	----		----
	\|-		\|-
	\|[[BRST5:Usual ductal hyperplasia]]		\|[[BRST5:Usual ductal hyperplasia\|Usual ductal hyperplasia]]
	\|Disease		\|Disease
	\|		\|